EMERGENT BIOSOLUTIONS INC (EBS)
Health Care · NYSE
Emergent BioSolutions supplies government-procured medical countermeasures for biodefense threats and commercial opioid overdose treatments, while operating a contract manufacturing services business.
What EMERGENT BIOSOLUTIONS INC does
Emergent BioSolutions is a global life sciences company providing innovative solutions for public health threats across chemical, biological, radiological, nuclear, and emerging infectious disease categories. The company operates through three segments: Commercial Products (naloxone-based opioid overdose treatments), Medical Countermeasures (government-procured vaccines and antivirals for threats like anthrax, smallpox, and mpox), and Bioservices (contract development and manufacturing services). Revenues derive from product sales, government procurement contracts, bioservices, and R&D funding from third parties.
Themes: ["Medical countermeasures / biodefense","Opioid overdose emergency response","CBRNE preparedness","Emerging infectious diseases / vaccines","Contract manufacturing / CDMO services","Government procurement"]
Fundamentals
- Price$8.18 as of 2026-07-09 close
- Market cap$430M as of 2026-07-10
- 1-year return+11.6% as of 2026-07-09 close
- P/E8.17 as of 2026-07-10
- Net margin-1.3% as of 2026-07-10
- Gross margin+54.3% as of 2026-07-10
- ROE-1.6% as of 2026-07-10
- Debt / equity1.10 as of 2026-07-10
- Revenue growth (YoY)-29.9% as of 2026-07-10
- Revenue CAGR (3y)-12.7% SEC XBRL
- Beta2.40 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on U.S. government funding and contracts for MCM products (anthrax, smallpox, botulism vaccines/antivirals), with risk of contract non-renewal or procurement delays","Intense commercial competition and generic marketplace pressures on NARCAN® naloxone products; declining revenue (-29.89% YoY as of filing date) and current unprofitability","Regulatory compliance, manufacturing quality, and ability to meet government delivery specifications and timelines; pending government investigations noted"]
Competitors & peers
- Bavarian Nordic
- Grifols (immunology/biologics)
- Meridian Bioscience
- Pfizer (vaccines, anthrax)
- Moderna (infectious disease vaccines)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.